ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Bortezomib Exhibits Therapeutic Implication in Renal Interstitial Fibrosis after Kidney Transplantation by Inhibiting Akt-mTOR-P70S6K-Smurf2 Pathway and Stabilizing IκBα Protein

C. Suo, Z. Gui, Z. Wang, J. Zhou, M. Zheng, H. Chen, S. Fei, L. Sun, X. Zhang, M. Gu, R. Tan

Jiangsu Province Hospital, Nanjing, China

Meeting: 2020 American Transplant Congress

Abstract number: C-372

Keywords: Epithelial cells, Fibrosis, Kidney transplantation

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session C: Immunosuppression Preclinical Studies

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • Bortezomib Attenuates the Progression of Epithelial to Mesenchymal Transition through Smurf1 Akt mTOR P70S6K Pathway in Rat Allograft Renal Interstitial Fibrosis Model
  • Renal Fibroblast Activation and Survival by Anti-MHC Class I Antibody: The Role of mTOR Signaling Pathway.

*Purpose: Allograft interstitial fibrosis and fibrogenesis significantly exacerbate the progression of chronic allograft disease (CAD) and are essential therapeutic targets. Epithelial‐mesenchymal transition (EMT) is recognized as an important source of myofibroblasts contributing to the pathogenesis of allograft interstitial fibrosis. We previously demonstrated that tumor necrosis factor‐alpha (TNF‐α) induced EMT via the TNF-α/Akt/Smurf2 signaling pathways in renal proximal tubule epithelial (HK-2) cells. Bortezomib (BZM) is a proteasome inhibitor used for the treatment of multiple myeloma (MM). Several studies have demonstrated that BZM prevents the progression of fibrosis in organs including kidney.

*Methods: To investigate the effect of BZM on allograft interstitial fibrosis and its mechanism both in vivo and in vitro. We used rat renal transplantation model and HK2 cell line treated with TNF-α to examine their response to BZM by assessing changes on morphology, renal function, expression of fibrosis/EMT related markers and evaluating cell movement. Besides, we explored the effect of BZM on TNF-α/Akt/Smurf2 signaling pathways. RNA sequencing was applied to assess the mechanism by which BZM inhibits the EMT. Based on RNA sequencing data, we further detected changes on NF-κB pathway.

*Results: BZM significantly attenuated renal allograft interstitial fibrosis and prevented allograft renal function impairment in vivo. In HK2 cell line, BZM inhibited the development of TNF-α-induced EMT as well as the abilities of motility and migration. In addition to blocking of Akt/mTOR/P70S6K/Smurf2 pathway, the antifibrotic effect of BZM on the EMT was associated with inhibition of NF-κB pathway by stabilizing IκBα protein.

*Conclusions: Our study suggests that BZM attenuates the development of TNF-α-induced EMT and renal allograft interstitial fibrosis, which provides novel insights into renal interstitial fibrosis and CAD following kidney transplantation. The results also highlight the therapeutic potential of BZM via its effect on NF-κB/TNF-α/Akt/mTOR/P70S6K/Smurf2 signaling pathways by stabilizing IκBα protein.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Suo C, Gui Z, Wang Z, Zhou J, Zheng M, Chen H, Fei S, Sun L, Zhang X, Gu M, Tan R. Bortezomib Exhibits Therapeutic Implication in Renal Interstitial Fibrosis after Kidney Transplantation by Inhibiting Akt-mTOR-P70S6K-Smurf2 Pathway and Stabilizing IκBα Protein [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/bortezomib-exhibits-therapeutic-implication-in-renal-interstitial-fibrosis-after-kidney-transplantation-by-inhibiting-akt-mtor-p70s6k-smurf2-pathway-and-stabilizing-i%ce%bab%ce%b1-protein/. Accessed April 20, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Penis Transplantation: First U.S. Experience.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.